Technical Trend Improvement Spurs Upgrade
The most significant catalyst behind the rating change is the alteration in the technical grade from bearish to mildly bearish. While the weekly and monthly Moving Average Convergence Divergence (MACD) indicators remain bearish and mildly bearish respectively, other technical signals suggest a tentative improvement. The weekly Dow Theory indicator has turned mildly bullish, and the On-Balance Volume (OBV) on a weekly basis also shows mild bullishness, signalling potential accumulation by investors.
However, some indicators remain cautious. The daily moving averages continue to be bearish, and the Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal. Bollinger Bands remain mildly bearish on both weekly and monthly timeframes, reflecting ongoing volatility and uncertainty. Overall, the technical landscape suggests a transition phase where the downtrend may be easing, but a definitive uptrend has yet to be established.
On 9 April 2026, Piramal Pharma’s stock price closed at ₹143.90, up 2.02% from the previous close of ₹141.05, with intraday highs reaching ₹146.45. The stock remains near its 52-week low of ₹134.70, far below its 52-week high of ₹241.00, underscoring the recent weakness in price action.
Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!
- - Recently turned profitable
- - Strong business fundamentals
- - Pre-breakout opportunity
Valuation Shifts from Fair to Attractive
Alongside technical improvements, Piramal Pharma’s valuation grade has been upgraded from fair to attractive. The company’s current price-to-earnings (PE) ratio stands at a negative -134.14, reflecting recent losses, but this contrasts sharply with its peers in the Pharmaceuticals & Biotechnology sector, many of whom trade at expensive or very expensive multiples. For example, Ajanta Pharma trades at a PE of 33.32, and J B Chemicals & Pharmaceuticals at 41.44.
Other valuation metrics reinforce this attractive stance. The enterprise value to EBITDA ratio is 22.82, while the enterprise value to capital employed is a modest 1.91, indicating the stock is trading at a discount relative to its asset base. The price-to-book value ratio is 2.38, which is reasonable given the sector context. The PEG ratio is 0.00, signalling no expected earnings growth, consistent with the company’s recent financial performance.
Return on capital employed (ROCE) is low at 2.66%, and return on equity (ROE) is negative at -0.55%, highlighting profitability challenges. Dividend yield remains negligible at 0.07%, reflecting the company’s focus on reinvestment or debt servicing rather than shareholder returns.
Financial Trend Remains Challenging
Despite the upgrade in technical and valuation grades, Piramal Pharma’s financial trend continues to be a concern. The company has reported negative results for three consecutive quarters, with profit before tax (PBT) excluding other income falling by a staggering 2,577.2% to a loss of ₹95.99 crores in the latest quarter. Net profit after tax (PAT) declined by 755.0% to a loss of ₹95.08 crores, and earnings per share (EPS) dropped to a low of -₹1.03.
Debt servicing remains a significant issue, with a high Debt to EBITDA ratio of 4.17 times, indicating limited capacity to manage leverage effectively. Net sales growth has been modest at an annual rate of 7.96% over the past five years, insufficient to offset profitability pressures. The company’s average return on equity over this period is a mere 0.32%, signalling low efficiency in generating shareholder value.
In terms of market performance, Piramal Pharma has underperformed the broader indices. Over the last year, the stock has declined by 35.02%, while the BSE500 index has gained 7.62%. Year-to-date returns are down 16.48%, compared to the Sensex’s 8.99% decline, reflecting persistent headwinds.
Long-Term Growth and Institutional Support
On a more positive note, the company has demonstrated healthy long-term growth in operating profit, which has increased at an annual rate of 111.53%. This suggests operational improvements that could support a future turnaround if sustained. Additionally, the stock’s three-year return of 110.34% significantly outpaces the Sensex’s 29.63% gain over the same period, indicating periods of strong performance in the past.
Institutional investors hold a substantial 45.35% stake in Piramal Pharma, reflecting confidence from knowledgeable market participants who possess the resources to analyse the company’s fundamentals thoroughly. This institutional backing may provide stability and support for the stock during volatile periods.
Considering Piramal Pharma Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Summary and Outlook
Piramal Pharma Ltd’s upgrade from Strong Sell to Sell reflects a nuanced view of the company’s prospects. While financial performance remains weak with consecutive quarterly losses and high leverage, the improved technical indicators and attractive valuation metrics provide a basis for cautious optimism. The stock’s discount relative to peers and signs of operational profit growth suggest potential for recovery, though risks remain significant.
Investors should weigh the company’s ongoing challenges against the possibility of a turnaround supported by institutional interest and improving market sentiment. The current rating implies that while the stock is not yet a buy, it may be moving away from the depths of a strong sell recommendation as conditions evolve.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
